Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research
Source abstract
Abstract
Cystic fibrosis (CF) is an autosomal recessive disorder resulting from impaired anion transport in the epithelium of multiple organs, thereby affecting various physiological functions throughout the body. The heterogeneity of CF complicates drug development, highlighting the growing importance of individualized therapies. CF patient-derived organoid models and organ-on-a-chip (OOC) platforms are promising in vitro models for recapitulating CF pathology, owing to their high simulation fidelity, individualized therapeutic capabilities, cost-effectiveness, and high-throughput screening potential. This review systematically summarizes the technological development pathways of patient-derived organoids and OOC platforms for CF, along with recent advances in their applications to CF-related basic research, and particularly focuses on exploratory studies using organoid-on-a-chip (OrgOC) systems to elucidate CF pathogenesis and assess therapeutic approaches.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cystic Fibrosis Research Advances · 3D Printing in Biomedical Research · Neonatal Respiratory Health Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Worldwide rates of diagnosis and effective treatment for cystic fibrosis10.1016/j.jcf.2022.01.009 ↗
2. Identification of the cystic fibrosis gene: chromosome walking and jumping10.1126/science.2772657 ↗
3. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA10.1126/science.2475911 ↗
4. CFTR function, pathology and pharmacology at single-molecule resolution10.1038/s41586-023-05854-7 ↗
5. Cystic fibrosis modulator therapies10.1146/annurev-med-042921-021447 ↗
6. Physiology and pathophysiology of human airway mucus10.1152/physrev.00004.2021 ↗
7. Cystic fibrosis10.1016/S0140-6736(16)00576-6 ↗
8. Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools10.1038/s41598-019-42404-6 ↗
9. Cystic fibrosis genetics: from molecular understanding to clinical application10.1038/nrg3849 ↗
10. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency10.1111/j.1572-0241.2000.02244.x ↗
11. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis10.1016/j.jpeds.2009.09.001 ↗
12. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis10.1378/chest.121.1.55 ↗
13. Safety, efficacy and convenience of tobramycin inhalation power in cystic fibrosis oatients: the eager trial10.1016/j.jcf.2010.10.003 ↗
14. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis10.1164/ajrccm.153.5.8630593 ↗
15. Other mucoactive agents for cystic fibrosis10.1016/j.prrv.2007.02.008 ↗
16. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches10.1016/S0140-6736(23)01608-2 ↗
17. Cystic fibrosis10.1016/S0140-6736(20)32542-3 ↗
18. Ion channel modulators in cystic fibrosis10.1016/j.chest.2018.04.036 ↗
19. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-77010.1073/pnas.0904709106 ↗
20. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation10.1056/NEJMoa0909825 ↗
21. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele10.1056/NEJMoa1908639 ↗
22. VX-445–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles10.1056/NEJMoa1807120 ↗
23. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy10.1016/S2213-2600(23)00324-7 ↗
24. Emerging nonpulmonary complications for adults with cystic fibrosis10.1016/j.chest.2021.11.001 ↗
25. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
26. Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis10.1371/journal.pgen.1007723 ↗
27. Infection in cystic fibrosis: impact of the environment and climate10.1586/17476348.2016.1162715 ↗
28. Influences of environmental exposures on individuals living with cystic fibrosis10.1080/17476348.2020.1753507 ↗
29. Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease10.1146/annurev-genom-083117-021329 ↗
30. Gene therapy for cystic fibrosis: new tools for precision medicine10.1186/s12967-021-03099-4 ↗
31. CFTR: cystic fibrosis and beyond10.1183/09031936.00228013 ↗
32. Animal models and their role in understanding the pathophysiology of cystic fibrosis–associated gastrointestinal lesions10.1146/annurev-pathol-022420-105133 ↗
33. Established cell lines used in cystic fibrosis research10.1016/j.jcf.2004.05.040 ↗
34. Cystic fibrosis–related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes10.2337/dc23-0380 ↗
35. CFTR modulator theratyping: current status, gaps and future directions10.1016/j.jcf.2018.05.004 ↗
36. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche10.1038/nature07935 ↗
37. Human organoids: model systems for human biology and medicine10.1038/s41580-020-0259-3 ↗
38. Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
39. Recent advances in lung organoid development and applications in disease modeling10.1172/JCI170500 ↗
40. Pluripotent stem cell-derived organoids: using principles of developmental biology to grow human tissues in a dish
41. Organ-on-a-Chip: a new paradigm for drug development10.1016/j.tips.2020.11.009 ↗
42. Human spinal Organoid-on-a-Chip to model nociceptive circuitry for pain therapeutics discovery10.1021/acs.analchem.1c04641 ↗
43. Organoids-on-a-chip for personalized precision medicine10.1002/adhm.202401843 ↗
44. Retinal organoids on-a-chip: a micro-millifluidic bioreactor for long-term organoid maintenance10.1039/D1LC00011J ↗
45. Human organoids-on-chips for biomedical research and applications10.7150/thno.90492 ↗
46. Organoids-on-a-chip10.1126/science.aaw7894 ↗
47. Organoids for drug discovery and personalized medicine10.1146/annurev-pharmtox-010818-021108 ↗
48. Engineering placenta‐like organoids containing endogenous vascular cells from human‐induced pluripotent stem cells
49. Animal and cell culture models for cystic fibrosis10.1016/j.ajpath.2020.10.017 ↗
50. Rectal organoids enable personalized treatment of cystic fibrosis10.1016/j.celrep.2019.01.068 ↗
51. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip10.1038/s41551-019-0397-0 ↗
52. Reconstituting organ-level lung functions on a chip10.1126/science.1188302 ↗
53. Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip在芯片上模拟人肺气道中的肺囊性纤维化10.1016/j.jcf.2021.10.004 ↗
54. Cerebral organoids model human brain development and microcephaly10.1038/nature12517 ↗
55. Self-organizing optic-cup morphogenesis in three-dimensional culture10.1038/nature09941 ↗
56. Tumor organoids: applications in cancer modeling and potentials in precision medicine10.1186/s13045-022-01278-4 ↗
57. Patient-derived cell models for personalized medicine approaches in cystic fibrosis10.1016/j.jcf.2022.11.007 ↗
58. Long‐term expanding human airway organoids for disease modeling10.15252/embj.2018100300 ↗
59. Intestinal organoids for cystic fibrosis research10.1016/j.jcf.2019.11.002 ↗
60. A multimodal iPSC platform for cystic fibrosis drug testing10.1038/s41467-022-31854-8 ↗
61. Pluripotent stem cell platforms for drug discovery10.1016/j.molmed.2018.06.009 ↗
62. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications10.1126/science.1234852 ↗
63. A functional CFTR assay using primary cystic fibrosis intestinal organoids10.1038/nm.3201 ↗
64. Differentiated human airway organoids to assess infectivity of emerging influenza virus10.1073/pnas.1806308115 ↗
65. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations10.1016/j.jcf.2019.10.022 ↗
66. Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with cystic fibrosis10.1016/j.jcf.2024.04.014 ↗
67. FDA-Approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes10.1016/j.jcf.2023.03.004 ↗
68. Evaluation of the complex p.[Leu467Phe;Phe508del] CFTR allele in the intestinal organoids model: implications for therapy10.3390/ijms231810377 ↗
69. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis10.1183/13993003.02426-2019 ↗
70. Drug repurposing for cystic fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoids10.3390/ijms232012657 ↗
71. High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing10.1183/23120541.00495-2022 ↗
72. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis10.1183/13993003.01661-2015 ↗
73. Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity10.1016/j.jcf.2018.02.007 ↗
74. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids10.1016/j.jcf.2015.07.007 ↗
75. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids10.1183/13993003.01192-2015 ↗
76. Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to elexacaftor (VX-445) and tezacaftor (VX-661) combination10.3390/ijms241210358 ↗
77. Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling10.1136/gutjnl-2016-312423 ↗
78. Airway and lung organoids from human-induced pluripotent stem cells can be used to assess CFTR conductance10.3390/ijms24076293 ↗
79. The sodium/glucose cotransporters as potential therapeutic targets for CF lung diseases revealed by human lung organoid swelling assay10.1016/j.omtm.2021.11.008 ↗
80. CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling10.1152/ajplung.00639.2020 ↗
81. Human nasal epithelial organoids for therapeutic development in cystic fibrosis10.3390/genes11060603 ↗
82. Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells10.1183/13993003.00908-2021 ↗
83. Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression10.1183/13993003.00508-2021 ↗
84. Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis10.26508/lsa.202201857 ↗
85. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis10.1016/j.jcf.2021.07.006 ↗
86. rAAV-CFTRΔR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice10.1164/rccm.201505-0914OC ↗
87. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis10.1126/scitranslmed.aad8278 ↗
88. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis
89. High-throughput functional analysis of CFTR and other apically localized proteins in iPSC-Derived human intestinal organoids10.3390/cells10123419 ↗
90. Human induced lung organoids: a promising tool for cystic fibrosis drug screening10.3390/ijms26020437 ↗
91. CFTR modulators rescue the activity of CFTR in colonoids expressing the complex allele10.3390/ijms24065199 ↗
92. A bioassay using intestinal organoids to measure CFTR modulators in human plasma10.1016/j.jcf.2014.10.007 ↗
93. The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators10.1152/ajplung.00038.2023 ↗
94. Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype10.1016/j.jcf.2022.01.008 ↗
95. Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation10.1016/j.jcf.2020.04.014 ↗
96. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers10.1016/j.jcf.2021.12.006 ↗
97. Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor/tezacaftor/ivacaftor10.1016/j.jcf.2024.09.005 ↗
98. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids10.1016/j.jcf.2021.01.009 ↗
99. Comprehensive assessment of CFTR modulators' therapeutic efficiency for N1303K variant10.3390/ijms25052770 ↗
100. Phenotyping of rare CFTR mutations reveals distinct trafficking and functional defects10.3390/cells9030754 ↗